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Abstract: Aims: We investigated the influence of body mass index (BMI) on the prevalence of responder status in chronic heart failure patients
after cardiac resynchronization therapy (CRT). Methods: Data on 169 patients with resynchronization therapy were analyzed. Patients were cate-
gorized on the basis of the BMI measured at device implantation according to the WHO classification, as normal (BMI: 18.5–24.9 kg/m2), over-
weight (BMI: 25–29.9 kg/m2) or obese (BMI:≥30 kg/m2). Patients were considered responders if left ventricular ejection fraction was increased
by at least 5% at 6-month follow-up. Results: The mean age in the study population was 60.9±10.86 years (females 29%). The BMI subgroups
did not exhibit any significant differences in baseline characteristics (age, gender, left ventricular ejection fraction or NYHA class). Elevated BMIs
were associated with higher prevalence of responder status (overweight: 71.4%, obese: 63.0%) relative to subjects with a normal BMI (44.7%)
(p=0.015). Conclusions: In this CRT population, overweight status was associated with a more favorable response to CRT, indicating that the re-
sponse may possibly be influenced by factors other than those directly related to the heart status or the technical details of the CRT.
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Introduction
Cardiac resynchronization therapy (CRT) has become a
well-established treatment modality which leads to better
quality of life, improves left ventricular ejection fraction
(LV EF) and decreases mortality in a selected group of
patients with chronic heart failure. However, a relatively
high proportion (20–40%) of such patients do not re-
spond to CRT according to most of the reports, in which
mostly functional end-points were used [1, 2]. A number
of factors (including the etiology of the cardiomyopathy,
the baseline QRS width, the positions of the right and
left ventricular leads and multiple echocardiographic pa-
rameters) have already been investigated as regards their
potential to predict a positive response to CRT. How-
ever, the results were either negative or conflicting, there-
fore an adequate predictor that could be used in routine
clinical practice is still lacking [3–9].
Obesity has rapidly become a major public health prob-
lem worldwide. The latest WHO statistics disclose that
32.2% of the general population in the United States is
obese, with a body mass index (BMI) exceeding 30
kg/m2 [10]. Elevated BMI is associated with well-known
cardiovascular risk factors, such as hypertension, diabetes
mellitus and dyslipidemia [11]. Indeed, excess weight it-
self is an independent risk factor for coronary artery dis-
ease, stroke, new-onset heart failure and death [12, 13].
Obesity-related myocardial abnormalities include dias-
tolic dysfunction, LV hypertrophy, increased LV end-di-
astolic diameter and in rare cases cardiomyopathy [14,
15]. Surprisingly, recent data indicate that elevated BMI
favorably alters the course of chronic heart failure, low-
ering the risk of hospitalization and death in overweight
and obese populations as compared with those with nor-
mal BMI [16–18]. In acute heart failure, a higher BMI
was also associated with lower in-hospital mortality [19].
In a small study involving patients with single or dual
chamber implantable cardioverter defibrillators, a higher
BMI was likewise associated with better survival [20].
The aim of the present study was to investigate the po-
tential influence of BMI on response to CRT: whether
elevated BMI is associated with a higher prevalence of a
responder status among patients with chronic heart fail-
ure and CRT?
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Materials and Methods
Patient population
The data on 229 consecutive patients who underwent
CRT (biventricular pacemaker or defibrillator) implan-
tation at our Department of Cardiology between Sep-
tember 2004 and August 2008 were reviewed. The 56
patients were excluded from the study because of miss-
ing data or a postimplantation follow-up shorter than 6
months. The 173 patients with complete baseline (in-
cluding adequate weight and height) and follow-up data
were analyzed retrospectively. CRT indications were:
impaired LV EF (<35%), LVEDD >55 mm, clinical
signs of heart failure (NYHA II–IV) and a sinus rhythm
with left bundle branch block (QRS complex duration
>120 msec). The underweight (BMI: ≤18.4 kg/m2)
patients (n=4) in our CRT population were subjects
with end-stage heart failure and cardiac cachexia and
were therefore excluded from further analysis. All pa-
tients received standard heart failure medical therapy
with beta-blockers, angiotensin–converter enzyme in-
hibitors and diuretics, including spironolactone.
BMI categories
Weight was measured daily throughout hospitalization.
To avoid the confounding effect of fluid retention in the
calculation of the BMI, the discharge weight was used
following intravenous diuretic therapy as necessary to
compensate the patient. BMI was calculated as the weight
in kilograms divided by the square of the height in me-
ters. Patients were categorized on the basis of the BMI
according to the WHO classification as normal (BMI:
18.5–24.9 kg/m2), overweight (BMI: 25–29.9 kg/m2)
or obese (BMI:≥30 kg/m2).
Definition of response to CRT
Echocardiography was performed prior to device im-
plantation and at every follow-up visit. LV diameters were
measured and EFs were calculated by the Quinones
method. The responder status was evaluated by echocar-
diographic measurements at 6-month follow-up: a pa-
tient was regarded as a responder if LV EF was improved
by at least 5% in absolute terms at 6-month follow-up.
The responder status was also defined by the improve-
ment in clinical status: a patient was considered respon-
der if their NYHA class status has been improved by at
least one class at 6-month follow-up compared to base-
line.
Statistics
Continuous variables are reported as means±standard
deviation, while categorical variables are presented as per-
centages. Stochastical correlations between discrete vari-
ables were investigated by means of chi2-test. Kol-
mogorov-Smirnov test was used for testing whether the
distribution is Gaussian or not. Groups of continuous
variables were compared by using the unpaired t-test and
the ANOVA test, as appropriate. P values <0.05 were
considered statistically significant. Statistical calculations
were performed by using Prism3 package.
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Table I Baseline patient characteristics classified according to BMI
Normal
(BMI 18.5–24.9)
Overweight
(BMI 25–29.9)
Obese
(BMI≥30) p value
n (%) 45 (26.6%) 70 (41.4%) 54 (32.0%)
Males (%) 29 (64.4%) 49 (70.0%) 42 (77.8%) 0.34
Age (yrs) 61.1 (±11.1) 62.5 (±11.2) 58.3 (±9.9) 0.10
CAD (%) 15 (33.4%) 22 (31.4%) 19 (35.2%) 0.91
Diabetes (%) 4 (8.9%) 14 (20.0%) 15 (27.8%) 0.06
Hypertension (%) 15 (33.4%) 33 (47.1%) 28 (51.2%) 0.16
NYHA
II 10 (22.2%) 13 (18.6%) 18 (33.3%) 0.15
III 27 (60%) 46 (65.7%) 29 (53.7%) 0.40
IV 8 (17.8%) 11 (15.7%) 7 (13.0%) 0.80
LV EF (%) 25.8 (±5.5) 26.5 (±8.2) 28.0 (±5.2) 0.25
LVESD (mm) 58.5 (±8.5) 59.2 (±11.3) 57.9 (±8.8) 0.77
LVEDD (mm) 69.6 (±8.5) 70.6 (±10.6) 70.0(±9.1) 0.85
CRT-D (%) 22 (48.9%) 33 (47.1%) 27 (50.0%) 0.95
Abbreviations: CAD – coronary artery disease, LV EF – left ventricular ejection fraction, LVESD – left ventricular end-systolic diameter, LVEDD – left ventricular end-
diastolic diameter, CRT-D – biventricular defibrillator
(Statistical tests used for comparing groups of data: Chi2, ANOVA)
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(104/169). Only 44.7% (20/45) of the patients with nor-
mal BMI were responders, whereas patients with elevated
BMI were more likely to exhibit a positive response to
CRT (p=0.015): 71.4% (50/70) of the overweight and
63.0% (34/54) of the obese. The odds ratio of overweight
patients displaying a positive response to CRT was 1.6 (CI:
1.12–2.30) relative to patients with normal BMI (Fig. 2).
The gender differences in response to CRT are pre-
sented in Table II. There was a tendency of higher re-
sponse rate among females in each category. Only 31%
of male patients in the normal weight group were re-
sponders.
By the improvement in functional status (at least one
NYHA class) 59.2% of the patients showed positive re-
sponse to CRT. Similarly to the echocardiographic re-
sults, the highest prevalence of responder status was
found in the overweight population (68.6%, 48/70),
whereas only 53.3% (24/45) of patients with normal
BMI and 51.9% (28/54) of the obese were regarded as
a responder, although the difference was not statistically
significant (p=0.111) (Fig. 3).
Additional observations
In several patients normalization of the LV EF (≥50%)
was observed after CRT. Although statistical analysis was
not feasible in these small subgroups (Fig. 4), the trend
was corresponding with the main results.
Over a mean follow-up of 23.4±11.1 months (range
6–50 months), a total of 13 deaths occurred in the study
population. Deaths during follow-up were more com-
Results
Patient characteristics
The baseline characteristics of each BMI subgroups of the
169 patients (females: 49 {29.0%}; mean age 60.9±10.86
years) are presented in Table I. There was an increasing
trend in the prevalence of diabetes in the obese population
relative to subjects with normal BMI, but the difference
did not reach statistical significance. The average LV EF in
the overall study population was 27±6.72%. Almost half
of the patients received biventricular implantable car-
dioverter defibrillator (CRT-D) in each BMI subgroups.
Only 26.6% of the patients were within the normal BMI
range, while 41.4% were overweight and 32% had BMI
≥30 (Fig. 1). The mean BMI was 28.7±5.2 for males,
and 27.0±4.2 for female patients (p=0.049).
Influence of BMI on responder status
Echocardiographic measurements indicated that the over-
all proportion of responders to CRT was 61.5%
BMI and responder status in patients after CRT
Fig. 1. Distribution of the study population according to BMI
Table II Response to CRT according to gender and BMI category
(Statistical test used for comparing groups of data: Chi2)
Normal Overweight Obese
Females (n=49) 8/16 (50.0%) 18/21 (85.7%) 9/12 (75.0%)
Males (n=120) 9/29 (31.0%) 31/49 (63.3%) 25/42 (59.5%)
Fig. 2. Prevalence of responder status in the normal, overweight
and obese groups evaluated by echocardiography (at least
5% improvement of the left ventricular EF). In the paren-
thesis: the proportion of the responder patients in each
group. (Statistical test used for comparing data: Chi2)
Fig. 3. The prevalence of responder status defined by improvement
in functional status (at least one NYHA class) relative to
baseline. In the parenthesis: the proportion of the respon-
der patients in each group. (Statistical test used for com-
paring data: Chi2)
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Obesity is a well-known independent risk factor for the
development of cardiovascular diseases, but it favorably
alters the prognosis in established chronic heart failure, a
phenomenon known as the “obesity paradox” [24]. This
“reverse epidemiology” has likewise been demonstrated
in other chronic, wasting diseases with a significantly re-
duced life expectancy, where obesity improved the short-
term prognosis [25]. The exact mechanism of the obesity
paradox is not fully understood. Proposed mechanisms
include increased hemodynamic stability in obesity, the
protective adipokine profile, the endotoxin-lipoprotein
hypothesis, the toxin sequestration of fatty tissue and the
antioxidative effect of muscle tissue. The proportion of
obese patients in our study population was 32%, while
only 27% of the patients had a BMI within the normal
range. These statistics are similar to those observed in the
general population of the USA and several countries of
the European Union, indicating that obesity is a major
problem, affecting a significant proportion of the popu-
lation, including those with chronic heart failure [10].
The phenomenon of the obesity paradox calls attention
to the fact that the relevant guidelines and initiatives
might need to distinguish between healthy individuals
and patients with certain chronic diseases. These latter in-
dividuals might require a different nutritional and weight
management strategy in order to optimize their life ex-
pectancy. Additionally, demonstration of the obesity par-
adox in relation to CRT outcome underscores the im-
portance of a multidisciplinary approach in a disease with
such an extensive potential influence on the neurohu-
moral status and metabolism.
According to our results the responder rate is the
highest in the overweight population, but is lower in
patients both with normal and very high (>30, obese)
BMI indicating that there is no linearity between BMI
and responder status. Although we found a remarkable
difference in the prevalence of responder status com-
paring obese patients to those with a normal BMI
(44.7% vs. 63.0%) the difference was not statistically sig-
nificant at this sample size (p=0.07). Similarly when the
responder status was defined by at least one NYHA class
improvement in the clinical status the comparable re-
sponder rate of obese patients and patients with normal
BMI (51.9% vs. 53.3%) might be partially explained by
the lower functional improvement of the obese due to
their excess weight.
Important limitations to our study must be noted. Pa-
tients with NYHA II functional class heart failure were
enrolled, though this is not an evidence-based indication
and is not included in guidelines at present. However, ac-
cording to the results of recent studies CRT in NYHA II
functional class patients with a poor LV function and a
left bundle branch block improves clinical outcome and
LV function [26, 27]. The enrollment of these patients
did not significantly change the results, as a similar rela-
tionship between BMI category and echocardiographic
improvement was observed in each functional class. Ad-
mon among non-responders 9/65 (13.4%) than among
responders 4/104 (3.8%), p=0.0176. There were 4
deaths (8.9%) in the normal BMI group, 4 (5.7%) in the
overweight group and 5 (10.2%) in the obese group.
Discussion
The “non-response” phenomenon in CRT patients has
been intensively studied almost since the clinical intro-
duction of this therapy. The clinical variables tested for a
possible correlation with the long-term outcome were
mostly related to technical aspects of the CRT, such as
lead positioning and device programming, functional sta-
tus of the heart, including the 12-lead ECG appearance
and several echocardiographic parameters measured prior
to implantation and other well-known prognostic factors
in CHF, e.g. the renal function and the serum level of
NT-proBNP. The main finding of our current work is
that the baseline BMI exhibits a clear correlation with the
improvement in echocardiographic parameters 6 months
after implantation. The very low (31%) response rate in
our male patients with normal weight was especially strik-
ing. As far as we are aware, the only previous study of the
BMI in patients after CRT was a post-hoc analysis of
CARE-HF in a search for potential predictors of long-
term outcome among baseline categorical variables and
continuous variables measured at baseline and 3 months
[21]. In CARE-HF, the BMI did not prove to be a pre-
dictor of long-term survival. In view of the relatively low
number of deaths among our patients, a potential rela-
tionship with mortality could not be statistically tested. In
this study responder status was defined 6 months after
device implantation by echocardiographic and functional
improvement as well. The rationale behind predicting the
long-term outcome after CRT by the early response is
that it simultaneously tests both the patient substrate and
the adequacy of the therapy. Earlier reports suggested
that changes in ventricular function, but not in symptoms
[22] or changes in the level of natriuretic peptides [23]
during the first 3–6 months did indeed predict the long-
term response to therapy.
Clemens et al.
Fig. 4. Proportion of patients with normalized left ventricular ejec-
tion fraction (EF≥50%) according to the BMI categories.
(Statistical test used for comparing data: Chi2)
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ditionaly, the Quinones method was used for echocar-
diographic calculation of the LV function, which is the
general practice of our echocardiographic team.
Conclusions
Higher BMI values were associated with a more favor-
able response to CRT, indicating that it might be influ-
enced by factors other than those directly related to the
heart status or the technical details of the CRT. Appro-
priate nutritional and weight management strategies need
to be developed for these patients.
References
1. Birnie DH, Tang ASL: The problem of non-response to cardiac re-
synchronization therapy. Curr Opin Cardiol 21, 20–26 (2006)
2. Freemantle N, Tharmanathan P, Calvert MJ, AbrahamWT, Ghosh
J, Cleland JGF: Cardiac resynchronisation for patients with heart
failure due to left ventricular systolic dysfunction — A systematic
review and meta-analysis. Eur J Heart Fail 8, 433–440 (2006)
3. Chung ES, Leon AR, Tavazzi L et al.: Results of the predictors of
response to CRT (PROSPECT) trial. Circulation 117, 2608–2616
(2008)
4. Mollema SA, Bleeker G, Wall van der E, Schalij M, Bax J: Useful-
ness of QRS duration to predict response to predict response to
cardiac resynchronization therapy in patients with end-stage heart
failure. Am J Cardiol 100, 1665–1670 (2007)
5. Gasparini M, Mantica M, Galimberti P et al.: Is the left ventricular
lateral wall the best lead implantation site for cardiac resynchroniza-
tion therapy. Pacing Clin Electrophysiol 26(1 Pt 2), 162–168 (2003)
6. Haghjoo M, Bonakdar HR, Jorat MV et al.: Effect of right ven-
tricular lead location on response to cardiac resynchronization ther-
apy in patients with end-stage heart failure. Europace 11, 356–363
(2009)
7. D’Ivernois C, Lesage J, Blanc P: Resynchronization: What if the
left ventricular lead cannot reach the lateral or posterolateral wall?
Pacing Clin Electrophysiol 31, 1041–1045 (2008)
8. Achilli A, Peraldo C, Sassara M et al.: Prediction of response to car-
diac resynchronization therapy: The selection of candidates for
CRT (SCART) study. Pacing Clin Electrophysiol 29 Suppl 2, S11–
S19 (2006)
9. Molhoek SG, Bax J, Erven van L et al.: Comparison of benefits
from cardiac resynchronization therapy in patients with ischemic
cardiomyopathy versus idiopathic dilated cardiomyopathy. Am J
Cardiol 93, 860–863 (2004)
10. World Health Organization: Global database of body mass index.
Available at: http://www.who.int/bmi/index.jsp. Accessed Janu-
ary 20, 2009
11. Krauss RM, Winston M: Obesity: Impact on cardiovascular disease.
Circulation 98, 1472–1476 (1998)
12. Kenchaiah S, Evans JC, Levy D et al.: Obesity and the risk of heart
failure. N Engl J Med 347, 305–313 (2002)
13. Poirier P,. Giles TD, Bray GA et al.: Obesity and cardiovascular dis-
ease: Pathophysiology, evaluation, and effect of weight loss: an up-
date of the 1997 American Heart Association Scientific Statement
on Obesity and Heart Disease from the obesity committee of the
Council of Nutrition, Physical Activity, and Metabolism. Circula-
tion 113, 898–918 (2006)
14. Divitiis O, Fazio S, Petitto M et al.: Obesity and cardiac function.
Circulation 64, 477–482 (1981)
15. Alpert MA, Terry BE, Mulekar M et al.: Cardiac morphology and
left ventricular function in normotensive morbidly obesee patients
with and without congestive heart failure, and effect of weight loss.
Am J Cardiol 80, 736–740 (1997)
16. Curtis JP, Selter JG, Wang Y et al.: The obesity paradox body mass
index and outcomes in patients with heart failure. Arch Intern Med
165, 55–61 (2005)
17. Bozkurt B, Deswal A: Obesity as a prognostic factor in chronic
symptomatic heart failure. Am Heart J 150, 1233–1239 (2005)
18. Davos CH, Doehner W, Rauchhaus M et al.: Body mass and sur-
vival in patients with chronic heart failure without cachexia: The
importance of obesity. J Card Fail 91, 891–894 (2003)
19. Fonarow GC, Srikanthan P, Costanzo MR et al.: An obesity para-
dox in acute heart failure: analysis of body mass index and inhos-
pital mortality for 108,927 patients in the Acute Decompensated
Heart Failure National Registry. Am Heart J 153, 74–81 (2007)
20. Schernthaner C, Pichler M, Strohmer B: Lower body mass index
and atrial fibrillation as independent predictors for mortality in pa-
tients with implantable cardioverter defibrillator. Croat Med J 48,
59–67 (2007)
21. Cleland J, Freemantle N, Ghio S et al.: Predicting the long-term ef-
fects of cardiac resynchronization therapy on mortality from base-
line variables and the early response. A report from the CARE-HF
(Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Car-
diol 52, 438–445 (2008)
22. Yu CM, Bleeker BG, Fung JW-H et al.: Left ventricular reverse re-
modeling but not clinical improvement predicts long-term survival
after cardiac resynchronization therapy. Circulation 112, 1580–
1586 (2005)
23. Kubanek M, Málek I, Bytesnik J et al.: Decrease in plasma B-type
natriuretic peptide early after initiation of cardiac resynchroniza-
tion therapy predicts clinical improvement at 12 months. Eur J
Heart Fail 8, 832–840 (2006)
24. Horwich TB, Fonarow GC, Hamilton MA et al.: The relationship
between obesity and mortality in patients with heart failure. J Am
Coll Cardiol 38, 789–795 (2001)
25. Kalantar-Zadeh K, Horwich TB, Oreopoulos A et al.: Risk factor
paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 10,
433–442 (2007)
26. Moss AJ, Hall WJ, Cannom DS et al.: Cardiac-resynchronization
therapy for the prevention of heart-failure events. N Engl J Med
361, 1329–1338 (2009)
27. Daubert C, Gold MR, Abraham WT et al.: Prevention of disease
progression by cardiac resynchronization therapy in patients with
asymptomatic or mildly symptomatic left ventricular dysfunction.
Insights from the European cohort of the REVERSE (Resynchro-
nization reverses remodeling in systolic left ventricular dysfunction)
trial. J Am Coll Cardiol 54, 1837–1846 (2009)
BMI and responder status in patients after CRT
IMAS_2010_1_imp(ff):IMAS_2010_3tord  3/16/10  4:33 PM  Page 21
